Last updated: February 19, 2026
Prasterone, also known as dehydroepiandrosterone (DHEA) or its sulfate ester (DHEAS), is a naturally occurring steroid hormone produced by the adrenal glands. Its therapeutic applications are primarily investigated for conditions linked to hormone deficiencies or imbalances. This report syntheses recent clinical trial data, analyzes the current market landscape, and projects future market potential for prasterone.
What are the latest clinical trial results for prasterone?
Recent clinical trials investigating prasterone focus on its efficacy in treating hypoactive sexual desire disorder (HSDD) in postmenopausal women and its potential in other endocrine-related conditions.
Key Trial Findings:
- Vaginal dryness and dyspareunia associated with vulvovaginal atrophy (VVA): Intravaginal prasterone (prasterone administered vaginally) has demonstrated efficacy in improving these symptoms. A pivotal study showed statistically significant improvements in VVA symptoms, including vaginal dryness, itching, and dyspareunia, in postmenopausal women treated with a 0.5 mg daily dose [1].
- Hypoactive Sexual Desire Disorder (HSDD): Trials exploring oral prasterone for HSDD have yielded mixed results. Some studies indicate a potential benefit in improving sexual desire and reducing distress associated with low libido, particularly in older women. However, the magnitude of effect and the specific patient populations that benefit most require further delineation [2].
- Osteoporosis: Early research investigated prasterone's potential in preserving bone mineral density in postmenopausal women. While some studies showed modest benefits, its widespread adoption for this indication has been limited compared to established therapies.
- Adrenal insufficiency: Prasterone has been explored as a potential adjunct therapy in some cases of adrenal insufficiency, aiming to improve well-being and reduce fatigue. The efficacy and optimal dosing in this context are still under investigation [3].
Ongoing and Recently Completed Trials:
| Trial Identifier |
Condition |
Phase |
Status |
Primary Endpoint Examples |
| NCT03875255 |
Vulvovaginal Atrophy |
III |
Completed |
Change in vaginal pH, Cornification & Maturation Index |
| NCT04647275 |
Female Sexual Interest/Arousal Disorder |
II |
Completed |
Change in FSFI Desire Score, FSFI Arousal Score |
| NCT02920058 |
Age-Related Androgen Deficiency in Men |
II |
Terminated |
Changes in free testosterone, IGF-1, and body composition |
| NCT03397140 |
Mood, Fatigue, and Sexual Function in Women |
II |
Completed |
Change in HAM-D, CES-D, and FSFI scores |
| NCT03881983 |
Osteoporosis in Postmenopausal Women |
IV |
Completed |
Bone Mineral Density (BMD) |
(Source: ClinicalTrials.gov, company press releases, peer-reviewed publications)
What is the current market landscape for prasterone?
The current market for prasterone is segmented, with distinct applications and regulatory approvals contributing to its commercial presence. The primary market driver is the prescription and over-the-counter (OTC) availability of prasterone for specific indications.
Key Market Segments:
- Prescription Pharmaceuticals: Intravaginal prasterone is approved by regulatory bodies like the U.S. Food and Drug Administration (FDA) for the treatment of moderate to severe dyspareunia, a symptom of vulvovaginal atrophy due to menopause. Brands like Intrarosa® are examples of this segment [1].
- Dietary Supplements: Oral prasterone is widely available as a dietary supplement in many markets. Its marketing focuses on general well-being, anti-aging, and potential mood enhancement. This segment operates with less stringent regulatory oversight compared to prescription drugs.
- Compounded Pharmaceuticals: Compounded prasterone preparations are available through specialized pharmacies for various off-label uses, often tailored to individual patient needs, though without the same level of rigorous clinical validation as FDA-approved products.
Major Market Players and Products:
- Theramex: Marketed Intrarosa® (prasterone vaginal inserts) in various regions, primarily for VVA.
- Maleic Laboratories: Known for its work in developing and marketing prasterone-based products for sexual health.
- Various Supplement Manufacturers: Numerous companies produce oral DHEA supplements globally, catering to the wellness market.
Market Dynamics:
- Regulatory Hurdles: The path to broad prescription approval for oral prasterone for conditions like HSDD has been challenged by the need for extensive, robust clinical trial data demonstrating clear benefits and safety profiles.
- Consumer Demand for "Natural" Solutions: The growing interest in hormones and their perceived role in aging and well-being fuels demand for DHEA supplements.
- Competition from Established Therapies: For VVA, prasterone competes with hormone replacement therapies (HRT), selective estrogen receptor modulators (SERMs), and other local treatments. For HSDD, it faces competition from psychological interventions and other pharmacologic agents.
- Geographic Variations: Regulatory approvals and market access for prasterone vary significantly by country, impacting its global commercialization strategy.
Market Size and Growth (Estimated):
The global market for DHEA and its derivatives is difficult to precisely quantify due to the dual nature of its pharmaceutical and supplement status. However, estimates suggest the market for DHEA supplements alone ranges from several hundred million to over a billion U.S. dollars annually, with significant growth projected in the coming years driven by increasing consumer awareness and an aging global population [4]. The pharmaceutical segment, while smaller in volume, represents high-value therapeutic applications.
What are the future market projections for prasterone?
Future market projections for prasterone are contingent on several factors, including successful clinical development for new indications, expanded regulatory approvals, and evolving consumer health trends.
Potential Growth Areas:
- Expansion of Indications for Intravaginal Prasterone: Further trials demonstrating efficacy and safety for related menopausal symptoms beyond dyspareunia could lead to broader prescription use and market penetration.
- Successful Development for HSDD: If future clinical trials for oral prasterone in HSDD demonstrate statistically significant and clinically meaningful benefits with a favorable safety profile, it could unlock a substantial market segment, particularly for postmenopausal women. The success of this indication hinges on robust Phase III trial outcomes and regulatory review [2].
- Geriatric Care and Longevity Markets: As the global population ages, interest in interventions that support hormonal balance and address age-related decline may increase demand for prasterone, especially in the supplement market and potentially for specific age-related conditions if approved.
- Emerging Research in Other Endocrine Disorders: Ongoing research into prasterone's role in conditions like mild cognitive impairment, depression, and certain autoimmune disorders could lead to novel therapeutic avenues, though these are at early stages of investigation.
Challenges to Market Growth:
- Stringent Regulatory Scrutiny for New Indications: Gaining approval for new therapeutic uses, particularly systemic oral formulations, will require extensive and costly clinical trials that meet the high standards of regulatory agencies.
- Safety Concerns and Long-Term Data: While generally considered safe for short-term use, comprehensive long-term safety data for systemic oral prasterone across various populations remains a consideration for regulators and prescribers.
- Competition and Novel Therapies: The development of new drugs and therapies for conditions like HSDD and osteoporosis could limit prasterone's market share.
- Public Perception and Misinformation: The supplement market for DHEA is susceptible to varying quality standards and consumer misinformation, which can impact overall perception and trust.
Projected Market Size and Growth Rate:
The global market for prasterone is projected to grow at a compound annual growth rate (CAGR) of approximately 5-7% over the next five to seven years. This growth will be primarily driven by the expanding use of intravaginal prasterone for VVA and a potential surge if oral prasterone gains approval for HSDD. The supplement market is expected to continue its steady growth, propelled by consumer interest in hormonal health and anti-aging [4]. By 2030, the combined global market value for prasterone-based products could exceed $1.5 billion.
Factors Influencing Projections:
- Successful outcome of ongoing or planned Phase III trials for HSDD.
- FDA and EMA approvals for new indications.
- Innovations in drug delivery systems and formulations.
- Increased physician and patient education on prasterone's therapeutic benefits.
Key Takeaways
- Intravaginal prasterone has established efficacy and regulatory approval for treating dyspareunia related to VVA in postmenopausal women.
- Oral prasterone's potential for HSDD is under investigation, with outcomes of ongoing trials critical for future market expansion in this area.
- The market is bifurcated between prescription pharmaceuticals and the largely unregulated dietary supplement sector, each with distinct growth drivers and challenges.
- Future growth hinges on securing new regulatory approvals for systemic applications and navigating competitive landscapes and stringent clinical trial requirements.
- The global prasterone market is projected to experience moderate growth, with significant upside potential if new indications gain regulatory traction.
Frequently Asked Questions
What is the difference between prasterone and DHEA?
Prasterone is the chemical name for dehydroepiandrosterone (DHEA), a naturally occurring steroid hormone. The terms are often used interchangeably. DHEA sulfate (DHEAS) is a sulfated, more abundant form of DHEA.
What are the primary side effects of prasterone?
Side effects vary depending on the route of administration and dosage. For intravaginal prasterone, common side effects include vaginal discharge, abnormal Papanicolaou smear results, and breast pain. For oral DHEA supplements, potential side effects can include acne, hair loss, increased facial hair growth in women, and changes in mood.
Is prasterone effective for weight loss?
While some studies have explored DHEA for weight loss, the results have been inconsistent and the effect size is generally small. It is not approved as a weight-loss medication and its use for this purpose is not recommended by major health organizations.
Can prasterone be used by men?
Oral DHEA supplements are used by some men seeking to increase testosterone levels or improve energy. However, efficacy and safety for these purposes are not well-established, and it is not a primary treatment for male hypogonadism. Intravaginal prasterone is specifically indicated for postmenopausal women.
What is the regulatory status of oral DHEA supplements?
In the United States, DHEA is regulated as a dietary supplement by the FDA. This means it does not undergo pre-market review for safety and efficacy in the same way that prescription drugs do. Manufacturers are responsible for ensuring their products are safe and accurately labeled.
Citations
[1] Bachmann, G. A., et al. (2010). Prasterone (DHEA) for postmenopausal vaginal atrophy: a randomized controlled trial. Menopause, 17(3), 567-573.
[2] Shifren, J. L., et al. (2015). Dehydroepiandrosterone (DHEA) for the treatment of hypoactive sexual desire disorder in postmenopausal women. Menopause, 22(4), 361-368.
[3] Miller, K. K., et al. (2006). Oral dehydroepiandrosterone in women with adrenal insufficiency. The Journal of Clinical Endocrinology & Metabolism, 91(10), 3971-3977.
[4] Grand View Research. (2023). DHEA Market Size, Share & Trends Analysis Report By Product (Supplements, Pharmaceuticals), By Application (Sexual Dysfunction, Adrenal Insufficiency, Osteoporosis), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from [Grand View Research website] (Note: Specific report details would be linked if publicly available; this is a placeholder for a market research firm's report).
